Tempest Therapeutics, Inc.
NASDAQTempest Therapeutics heads into a complex moment: the Q1 print has already landed, and it's a miss — but the stock rose 13.6% the day before, and short sellers have been trimming exposure throughout. The headline print is ugly. Q1 adjusted EPS came in at -$0.50, well below the -$0.28 estimate. With zero revenue and an annualised net loss running near $20 million, the company…
Snapshot as of 15 May 2026
Tempest Therapeutics heads into a complex moment: the Q1 print has already landed, and it's a miss — but the stock rose 13.6% the day before, and short sellers have been trimming exposure throughout. The headline print…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TPST — free to start on ORTEX.
Sign up for free →Open TPST on ORTEX